BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma
Phase 2
Completed
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 83
- Registration Number
- NCT00492297
An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1150
- Registration Number
- NCT00492986
Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving ED
Phase 3
Completed
- Conditions
- Erectile DysfunctionSexual Dysfunction, Physiological
- Interventions
- Drug: PlaceboDrug: Levitra (Vardenafil, BAY38-9456)
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 628
- Registration Number
- NCT00492635
Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem
Phase 3
Completed
- Conditions
- Infection
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2014-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 804
- Registration Number
- NCT00492726
Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis
Phase 4
Terminated
- Conditions
- SinusitisBacterial Infections
- Interventions
- Drug: Amoxicillin/ClavulanateDrug: Moxifloxacin (Avelox, BAY12-8039)
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2014-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 293
- Registration Number
- NCT00493038
A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Phase 3
Completed
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Drug: Sorafenib (Nexavar, BAY43-9006)Drug: Placebo
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 226
- Registration Number
- NCT00492752
Multicenter Clinical Study to Examine the Efficacy and Safety of Zarzenda in Patients With Hand Eczema
Phase 4
Completed
- Conditions
- Hand Eczema
- Interventions
- Device: Zarzenda
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 40
- Registration Number
- NCT00488241
- Locations
- 🇩🇪
Intendis GmbH, Berlin, Germany
Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens
Phase 4
Completed
- Conditions
- Urinary Tract Infections
- First Posted Date
- 2007-06-04
- Last Posted Date
- 2009-06-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 500
- Registration Number
- NCT00481689
A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function
Phase 2
Completed
- Conditions
- Overactive BladderDetrusor Overactivity
- Interventions
- Drug: Vardenafil HCl (Levitra, BAY38-9456)Drug: Placebo
- First Posted Date
- 2007-05-25
- Last Posted Date
- 2014-12-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 397
- Registration Number
- NCT00478881
Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis
Phase 3
Completed
- Conditions
- Bronchitis, ChronicLung Diseases
- Interventions
- Drug: PlaceboDrug: Avelox (Moxifloxacin, BAY12-8039)
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1404
- Registration Number
- NCT00473460
© Copyright 2025. All Rights Reserved by MedPath